India UK FTA API Exports: What Buyers and Exporters Need
India–UK Trade Deal and API Exports: What Buyers and Exporters Need to Know The India–UK trade agreement, formally the Comprehensive Economic and Trade Agreement (CETA), entered into force on July 15, 2026. For pharmaceutical companies, the headline is easy to repeat: duty-free or reduced-duty access to the UK market. For anyone sourcing or exporting active […]
US Pharma Tariffs 2026 India: Updated for API Buyers
US Pharma Tariffs 2026: What API Buyers Need to Know (Updated October 16, 2026) If you buy or sell active pharmaceutical ingredients, the US pharma tariffs 2026 India discussion has changed twice since spring. First came a 100% tariff on patented medicines. Then, in July, the US president announced a plan that could eventually reach […]
India Pharma Exports to Brazil: Why Brazil Matters in 2026
Why Brazil Is One of India’s Biggest Pharma Export Markets For years, the conversation about India pharma exports to Brazil sat in the shadow of the US and Europe. The latest data suggests that is changing. In Pharmexcil figures for April–June of FY2026-27, Brazil appears directly behind the United States among India’s top pharmaceutical export […]
API Supply Chain Fragility: What the New US Index Means
What the New US “Fragility Index” Means for API Buyers On October 6, 2026, the API Innovation Center (APIIC), a St. Louis-based nonprofit, launched the National Fragility Index (NFI), described as the first benchmark built to measure and track structural fragility across U.S. pharmaceutical supply chains. For anyone who buys active pharmaceutical ingredients, the headline […]
Azithromycin API Price Trend 2026: Planning Q4 Orders
Azithromycin API Price Trend 2026: Planning Q4 Orders and Seasonal Restocking Every autumn, the same question lands on procurement desks: should we order Azithromycin API now, or wait? The Azithromycin API price trend 2026 gives a fairly calm answer on price, since recent quarterly movement has been small, but a less calm answer on timing, […]
Tofacitinib Generic Rheumatoid Arthritis API: What’s Next
Tofacitinib Generics in 2026: What the RA Small-Molecule Shift Means for csDMARD Formulators Pfizer’s Xeljanz (tofacitinib) is one of several widely prescribed small-molecule drugs reaching loss of exclusivity in 2026, and the tofacitinib generic rheumatoid arthritis API market is starting to take shape as a result. For formulators and API buyers working in rheumatology, this […]
Tadalafil API CoA Parameters: A Line-by-Line Guide
Understanding Tadalafil API CoA Parameters: A Line-by-Line Guide Most buyers glance at a Certificate of Analysis, check that every row says “Complies” or “Pass,” and move on. That’s understandable CoAs are dense, test-method-heavy documents — but it also means a lot of buyers never actually learn what each parameter is testing for, or why a […]
Niche API Manufacturer Premium Valuation: Why Investors Pay More
The active pharmaceutical ingredient (API) industry has long been seen as a volume game: high output, thin margins and constant pricing pressure from generic buyers. Yet a quiet shift is under way. Private equity firms, strategic acquirers and institutional investors are increasingly willing to pay more for smaller, specialized producers. The niche API manufacturer premium […]
MFN Pharma Deals SAPIR Stockpile: Impact on API Exporters
How the New MFN Pharma Deals and SAPIR Stockpiles Impact Generic API Exporters A series of US policy moves through 2025 and 2026 have been quietly reshaping the incentives around where active pharmaceutical ingredients get sourced from and the latest wave of developments deserves more attention from generic API exporters than it’s getting. Between steep […]